Mankind Pharma Limited has completed the allotment of 23,256 equity shares under its Employee Stock Option Plan 2022, as approved by the Nomination and Remuneration Committee through a circular resolution passed on March 16, 2026. The shares were allotted to eligible employees who exercised their stock options under the company's ESOP scheme.

Share Allotment Details

The allotment represents a strategic move to reward employee participation in the company's growth through equity ownership. The key parameters of this ESOP allotment are structured as follows:

Impact on Share Capital

The allotment has resulted in an expansion of the company's equity base, reflecting the successful implementation of its employee incentive program. The capital structure changes are detailed below:

Regulatory Compliance and Share Characteristics

The allotment has been executed in compliance with Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The newly issued shares carry the same rights and privileges as existing equity shares, with no lock-in restrictions applicable.

Key regulatory aspects include:

• SEBI Filing Reference: Originally filed on September 27, 2023
• Stock Exchange Listing: NSE and BSE
• ISIN Number: INE634S01028
• Share Ranking: Pari-passu with existing equity shares

Corporate Governance Framework

The ESOP allotment demonstrates Mankind Pharma's commitment to aligning employee interests with shareholder value creation. The Employee Stock Option Plan 2022 serves as a retention and motivation tool for eligible employees, allowing them to participate in the company's long-term growth trajectory.

The company has fulfilled all disclosure requirements by informing both NSE and BSE about the allotment and updating the information on its official website at www.mankindpharma.com . This transparent approach ensures all stakeholders remain informed about changes in the company's capital structure.

Mankind Pharma Limited has issued a clarification to BSE Limited regarding the recent surge in trading volume of its shares, attributing the increase to prevailing market conditions while reaffirming its commitment to regulatory compliance.

BSE Inquiry and Company Response

The clarification came in response to a BSE email dated February 27, 2026, which sought explanation for the increased volume in Mankind Pharma's securities across exchanges. Company Secretary and Compliance Officer Hitesh Kumar Jain signed the response, addressing the exchange's concerns about the unusual trading activity.

Regulatory Compliance Confirmation

Mankind Pharma emphasized that it maintains prompt disclosure practices as specified under Part A of Schedule III of Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The company stated it has not withheld any material information that could influence the price or volume behavior of its shares.

The pharmaceutical company clarified that the recent volume increase appears to be purely driven by market conditions, noting that it cannot comment specifically on such volume fluctuations. This response indicates the company's position that no undisclosed corporate developments or material events contributed to the trading surge.

Governance Standards

The company reiterated its commitment to maintaining the highest standards of governance and compliance norms. Mankind Pharma assured that it continues to make timely disclosures to stock exchanges under all applicable regulations, including Regulation 30 of the Listing Regulations.

The formal communication was digitally signed by Hitesh Kumar Jain on February 27, 2026, at 13:23:02 +05'30', demonstrating the company's prompt response to regulatory inquiries and adherence to digital documentation standards.